{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:49:57Z","timestamp":1761058197826},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":4848,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1991,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic inflammatory demyelinating polyneuropathy is an immune\u2010mediated demyelinating peripheral neuropathy usually treated with immunosuppressants. We reviewed our experience treating 15 patients (9 men, 6 women) with intravenous immunoglobulin. Six patients were on other therapies at the time of intravenous immunoglobulin infusions (4, prednisone; 2, prednisone and azathioprine). The dose of intravenous immunoglobulin was either 0.3 or 0.4 gm\/kg\/day for 4 to 5 days. Transient fever occurred in 1 patient. Subjective improvement in sensory symptoms was reported by almost all patients. Objective improvements in strength or functional tasks occurred in only 3 patients, a man with human immunodeficiency virus infection, a 14\u2010year\u2010old girl, and a woman with an immunoglobulin G kappa paraprotein. Our results suggest that individual patients may respond to intravenous immunoglobulin therapy. A multicenter controlled trial is needed to assess properly the role of intravenous immunoglobulin therapy in patients with chronic inflammatory demyelinating polyneuropathy.<\/jats:p>","DOI":"10.1002\/ana.410300119","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T12:01:12Z","timestamp":1104580872000},"page":"104-106","source":"Crossref","is-referenced-by-count":63,"title":["Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin"],"prefix":"10.1002","volume":"30","author":[{"given":"David R.","family":"Cornblath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb27058.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410110205"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602203140801"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(85)90173-X"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.3.422"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.209"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.212"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02335733"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1987.00520150004002"},{"key":"e_1_2_1_11_2","first-page":"853","article-title":"Electrophysiologic studies in patients with chronic inflammatory demyelinating polyneuropathy treated with intravenous immune globulin","volume":"13","author":"Teasley JE","year":"1990","journal-title":"Muscle Nerve"},{"key":"e_1_2_1_12_2","first-page":"238","article-title":"Comparison of treatment for chronic inflammatory demyelinating polyneuropathy","volume":"28","author":"Ropper AH","year":"1990","journal-title":"Ann Neurol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880120811"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530140113024"},{"key":"e_1_2_1_15_2","volume-title":"Intravenous gammaglobulin therapy","author":"Garner RJ","year":"1988"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410300119","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410300119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:37:44Z","timestamp":1698021464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410300119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991,7]]}},"alternative-id":["10.1002\/ana.410300119"],"URL":"https:\/\/doi.org\/10.1002\/ana.410300119","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,7]]}}}